Literature DB >> 30393166

Dendrimer-like mesoporous silica nanospheres with suitable surface functionality to combat the multidrug resistance.

Weixia Xu1, Xiaofeng Gao1, Pengjin Ge1, Fuquan Jiang1, Xiaokun Zhang1, Jingjing Xie2.   

Abstract

Multidrug resistance (MDR), as a major obstacle in cancer therapy, has resulted in over 90% of cancer chemotherapeutic failure. Mesoporous silica nanospheres (MSNs) have been demonstrated to be tuned with large pore sizes, mediating the MDR-reversal effects. However, the study that surface functionality of the large pore sized-MSNs affects the MDR-overcoming effects hasn't been extensively studied. In this study, we developed a new dendrimer-like MSNs delivery system based on a rational synthesis strategy and further modified MSNs with various surface functionalities to evaluate their roles in overcoming cancer MDR. Our results showed that the small particle sized-MSNs could be fabricated with dendrimer-like internal structure, resulting in the large pore size of 9 nm. Surface functionality of MSNs, especially hydroxylation and carboxylation, largely improved the intra-nuclear delivery and therapeutic efficiency of DOX for MCF7/ADR cells, which was not up to inhibiting P-gp expression but significantly increasing the intracellular drug accumulation of over 90% even under the strong drug efflux. This study indicates that surface functionality design strategy may display the potential of the large pore sized-MSNs as the efficient chemotherapeutic carriers to combat MDR.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer therapy; Large pore size; Mesoporous silica nanospheres; Multidrug resistance; Surface functionality

Mesh:

Substances:

Year:  2018        PMID: 30393166     DOI: 10.1016/j.ijpharm.2018.10.056

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  1 in total

Review 1.  Recent advances in anti-multidrug resistance for nano-drug delivery system.

Authors:  Changduo Wang; Fashun Li; Tianao Zhang; Min Yu; Yong Sun
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.